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Abstract
Introduction: There are little data about patients with cardiogenic shock (CS) who survive the early phase of acute
myocardial infarction (AMI). The aim of this study was to assess long-term (5-year) mortality among early survivors
of AMI, according to the presence of CS at the acute stage.
Methods: We analyzed 5-year follow-up data from the French registry of Acute ST-elevation and non-ST-elevation
Myocardial Infarction (FAST-MI) 2005 registry, a nationwide French survey including consecutive patients admitted
for ST or non-ST-elevation AMI at the end of 2005 in 223 institutions.
Results: Of 3670 patients enrolled, shock occurred in 224 (6.1%), and 3411 survived beyond 30 days or hospital
discharge, including 99 (2.9%) with shock. Early survivors with CS had a more severe clinical profile, more
frequent concomitant in-hospital complications, and were less often managed invasively than those without CS.
Five-year survival was 59% in patients with, versus 76% in those without shock (adjusted hazard ratio (HR) = 1.72
[1.24-2.38], P = 0.001). The excess of death associated with CS, however, was observed only during the first year
(one-year survival: 77% vs 93%, adjusted HR: 2.87 [1.85 to 4.46] P <0.001), while survival from one to 5 years was
similar (76% vs 82%, adjusted HR: 1.06 [0.64 to 1.74]). Propensity score-matched analyses yielded similar results.
Conclusions: In patients surviving the early phase of AMI, CS at the initial stage carries an increased risk of death up to
one year after the acute event. Beyond one year, however, mortality is similar to that of patients without shock.
Trial registration: ClinicalTrials.gov number, NCT00673036, Registered May 5, 2008.
Introduction
Despite considerable progress in the management of
patients admitted for acute myocardial infarction (AMI),
cardiogenic shock (CS) remains a major complication
[1,2]. In-hospital mortality has declined due to early revas-
cularization and improved overall management, however,
early mortality rates remain high; only about 50% of AMI
patients developing CS are alive at one month [1-4].
Little data exist on the long-term outcomes of patients
surviving the acute phase of CS following AMI [4-6].
Most studies report that patients with CS have an in-
creased risk of death up to one year after the acute event.
Beyond 1 year, mortality seems to be similar to that of
patients without CS. However, most of these studies were
performed in the 1990s., Marked reductions in AMI
mortality have recently been reported, including among
patients with CS [4-6].
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The French registry of Acute ST-elevation and non-
ST-elevation Myocardial Infarction (FAST MI) 2005 regis-
try is a prospective, nationwide, observational study con-
ducted at the end of 2005 in a large number of the French
hospitals treating AMI patients [7,8]. It allows evaluation
of the long-term outcome in acute ST-elevation and
non-ST-elevation myocardial infarction patients with
and without CS. The aim of the present study was to ana-
lyse long-term outcomes of early survivors of the acute
phase, according to the presence of CS at the acute stage.
Materials and methods
Study population
The methods of the FAST-MI 2005 registry have been
described in detail elsewhere [7,8]. Briefly, the primary
objectives were to evaluate myocardial infarction (MI)
management in real-life practice and to assess short- and
long-term outcomes of patients admitted to ICUs for MI.
Patients were consecutively recruited from ICU depart-
ments over a period of 1 month (October to November
2005), with a 1-month extension for patients with known
diabetes mellitus. Participation in the study was offered to
all French institutions, university teaching hospitals, gen-
eral and regional hospitals, and private clinics with ICUs
authorized to receive acute coronary syndromes (ACS). In
each centre, a physician was in charge of the registry and
provided a full list of all patients admitted to the unit. The
number of participating centres was 223, representing
60% of all centres taking care of AMI patients in France at
that time.
Inclusion criteria were (1) men or women, over 18 years
old; (2) patients admitted within 48 h after symptom onset
in an ICU for an AMI characterized by increased troponin
or creatine kinase-MB associated with at least one of the
following elements: symptoms compatible with myocar-
dial ischaemia, appearance of pathologic Q-waves, or
ST-T changes compatible with myocardial ischaemia
(ST-segment elevation or depression, T-wave inversion);
and (3) consent to take part in the study. Patients who
died very soon after admission and for whom cardiac
markers were not measured were included if they had
compatible signs or symptoms associated with typical
ST-segment changes. Exclusion criteria were (1) refusal
to participate; (2) patients with MI who were admitted
more than 48 h after symptom onset; (3) patients with
iatrogenic MI, defined as MI occurring within 48 h of a
therapeutic procedure (bypass surgery, coronary angio-
plasty, or any other medical or surgical intervention);
(4) ACS diagnosis invalidated in favour of another diagno-
sis; and (5) patients with unstable angina and no increase
in cardiac biomarkers.
CS was defined as systolic blood pressure <90 mm Hg
for ≥1 h not responsive to fluid administration alone,
thought to be secondary to cardiac dysfunction, and
associated with signs of hypoperfusion or cardiac index
≤2.2 l/min/mm2 and pulmonary capillary wedge pres-
sure >18 mm Hg [9,10].
All patients provided informed consent for their par-
ticipation in the registry. The protocol was reviewed
by the Committee for the Protection of Human Subjects
in Biomedical Research of St Antoine University Hospital
and the data file of the study was declared to and au-
thorized by the French data protection committee (Com-
mission Nationale Informatique et Liberté). Participating
physicians were asked not change their usual therapeutic
approach for the purpose of the survey. All the au-
thors vouch for the fidelity of the study to the trial
protocol, which is available at ClinicalTrials.gov number,
NCT00673036 (Registered 5 May 2008).
Overall, 3,670 patients were included in the survey.
Among them, 224 (6.1%) developed shock: 259 patients
died in hospital or during the first 30 days following
admission, and 3,411 patients survived the early phase
(patients surviving the initial hospital stay and alive at
30 days) and were included in the present study.
Data collection
Baseline characteristics, namely demographics (age, gen-
der), risk factors (hypertension, body mass index >30 kg/
m2, diabetes, current smoking, hyperlipidaemia, family
history), medical history (previous AMI, previous percu-
taneous coronary intervention (PCI), previous coronary
artery bypass grafting, previous stroke, previous heart
failure, prior peripheral arterial disease, previous chronic
renal failure, previous chronic obstructive pulmonary
disease and previous cancer), and previous medications
(antiplatelet agents, statins, angiotensin-converting enzyme
(ACE) inhibitors, angiotensin-receptor blockers (ARB)s,
beta-blockers and insulin) were collected prospectively and
stored electronically as previously described.
Clinical presentation, and glycaemia at the time of
admission were also collected and the last value of left
ventricular ejection fraction (LVEF) during the hospital
stay was recorded. We also recorded the use of cardiac
procedures, in-hospital complications (re-infarction, stroke,
major bleeding, the need for transfusion, ventricular fibril-
lation, new atrial fibrillation and second-and third-degree
atrio-ventricular (AV) block) and medications (antiplatelet
agents, diuretics, beta-blockers, ACE-inhibitors and lipid-
lowering agents) used in the first 48 h and at hospital
discharge in early CS survivors.
Outcome
Mortality was assessed at 1 and 5 years both in patients
with and without CS, who were discharged alive and were
alive at one month (early survivors). Follow up was centra-
lised at the French Society of Cardiology and dedicated re-
search technicians contacted both physicians and patients
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themselves, after checking patients’ vital status in munici-
pal registries. Causes of death were obtained by direct
contact with patients’ physicians or families, and from
the national causes of death registry. Two cardiologists,
unaware of patients’ hospital course, adjudicated causes
of death as cardiovascular, non-cardiovascular, or un-
known. The rate of patients lost to follow up was 0.3% at
1 year, 2% at 3 years and 5% at 5 years.
Statistical analysis
Statistical analysis was performed using IBM SPSS 20.0
(IBM SPSS, Inc., Armonk, NY, USA) and NCSS 9.0.7
(NCSS, LLC. Kaysville, UT, USA). For quantitative vari-
ables, mean and standard deviations were calculated.
Discrete variables are presented as percentages. Compar-
isons were performed with the chi-square or Fisher’s
exact test for discrete variables and with the unpaired
t-test, or Wilcoxon sign-rank tests for continuous vari-
ables. Odds ratios (OR) or hazard ratios (HR) are pre-
sented with the 95% CI. Five-year mortality rates were
calculated using the Kaplan-Meier method and compari-
sons were made using log-rank tests.
Because coronary artery disease remains unstable for
several months after an acute coronary syndrome, and
potent antithrombotic medications, such as dual anti-
platelet therapy, are recommended for 1 year following
AMI, we selected the 1-year time point for performing
landmark analyses: the analyses were performed with
1-year survival as the dependent variable in the popu-
lation of early survivors, and 5-year survival as the
dependent variable in the population of patients alive at
one year [11].
Correlates of 5-year mortality were determined using a
multivariate Cox backward analysis. The cumulative haz-
ard functions for each covariable were computed to assess
proportionality, and colinearity was verified by calculating
variance inflation factors. Shock was analysed as a time-
dependent variable, with the time-point set at 12 months
from the acute episode. Variables included in the final
multivariate models were selected ad hoc, based upon
their physiological relevance and potential to be associated
with outcomes; thus, we included variables likely to influ-
ence outcome negatively (age, history of heart failure, his-
tory of diabetes, history of prior AMI, history of stroke,
history of peripheral artery disease, anemia on admission)
or positively (history of hypertension, current smoking,
revascularisation by percutaneous coronary intervention
or surgery, early use of low molecular weight heparin,
glycoprotein IIB-IIIa inhibitors, and discharge medica-
tions: aspirin, clopidogrel, statins, ACE-inhibitors, ARBs,
beta-blockers) as well as sex, type and region of institu-
tion, and type of MI (segment-elevation myocardial infarc-
tion (STEMI) versus non-segment-elevation myocardial
infarction (NSTEMI).
In addition, to assess the potential role of CS on late
mortality, we calculated propensity scores for having
presented CS, using logistic regression analysis 1) in
patients alive at hospital discharge and at 30 days, and 2)
in patients who were alive at one year (c-statistic = 0.76
for both propensity scores). Cohorts with and without
CS were constituted, matched on the propensity scores
(3-to-1 matching: population of early survivors, 94 pa-
tients with CS, 282 patients without CS; population of
1-year survivors, 73 patients with CS, 217 patients with-
out CS), and their outcomes were compared using log-
rank tests. For calculating the propensity scores, we
used baseline characteristics, early management including
revascularisation procedures and antithrombotic medica-
tions, in-hospital complications (re-infarction and major
bleeding) and discharge medications. LVEF and medi-
cations indicated for heart failure (renin angiotensin aldos-
terone inhibitors and beta-blockers) were not included in
the model to avoid over-adjustment. For all analyses, a
P-value <0.05 was considered significant.
Results
Baseline characteristics of all 30-day survivors
Among the 3,411 early survivors, 99 (2.9%) had developed
CS at the acute stage. Patients with CS were significantly
older and had more comorbid conditions (Table 1). Clin-
ical presentation at admission of patients with CS was
more severe, and they had developed more complications
during hospitalization. The use of revascularization proce-
dures was comparable in the two groups.
Five-year survival
Five-year survival was 59% in early survivors with CS,
compared with 76% in early survivors without shock
(P <0.001) (Figure 1).
Landmark analyses in the overall population
One-year survival was 93% in early survivors without CS
and 77% in patients with CS. Cause of death analysis
showed that cardiovascular death was as frequent in CS
patients (65.2%) as in non-CS patients (66.3%). Five-year
survival was 76% in the 76 CS patients surviving at one
year, versus 82% in the 3,072 non-CS patients surviving
at one year (an additional table shows this in more
detail; see Additional file 1). Beyond 1 year, there was a
non-significant trend towards increased cardiovascular
mortality in CS patients (55.6% versus 36.3%), but with
fewer deaths of unknown cause (22.2% versus 31.1%).
In the time-dependent Cox multivariate model, CS
was independently associated with increased hazard for
death at 12 months (HR: 2.87, 95% CI: 1.85, 4.46, P <0.001),
but carried no increased risk from 1 year to 5 years
(HR 1.06, 95% CI: 0.64, 1.74).
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Table 1 Baseline characteristics of patients surviving at 30 days and hospital discharge according to presence of
cardiogenic shock at the acute stage
No shock (n = 3,312) Shock (n = 99) P-value
Age, years, mean ± SD 66 ± 14 70 ± 13 <0.001
Sex, female, n (%) 1014 (30.6) 37 (37.4) 0.43
Body mass index, Kg/m2, mean ± SD 27.2 ± 4.7 26.5 ± 4.9 0.15
Risk factors, n (%)
Hypertension 1949 (58.8) 62 (62.6) 0.45
Diabetes mellitus 1166 (35.2) 37 (37.4) 0.65
Current smoking 990 (29.9) 27 (27.3) 0.59
Hypercholesterolemia 1622 (49.0) 44 (44.4) 0.37
Family history of coronary artery disease 796 (24.0) 11 (11.1) 0.003
Previous medical history, n (%)
Myocardial infarction 591 (17.8) 23 (23.2) 0.17
Percutaneous coronary intervention 472 (14.3) 13 (13.1) 0.75
Coronary artery bypass graft 186 (5.6) 8 (8.1) 0.30
Stroke 168 (5.1) 5 (5.1) 0.99
Peripheral arterial disease 316 (9.6) 17 (17.2) 0.01
Heart failure 172 (5.2) 9 (9.1) 0.09
Chronic kidney disease 172 (5.2) 6 (6.1) 0.71
Chronic obstructive pulmonary disease 141 (4.3) 9 (9.1) 0.02
Cancer 218 (6.6) 4 (4.0) 0.31
Previous medications, n (%)
Antiplatelet agents 1058 (31.9) 35 (35.4) 0.47
Statins 930 (28.1) 32 (32.4) 0.35
Angiotensin-converting enzyme inhibitor 640 (19.3) 33 (33.3) 0.001
Angiotensin receptor blockers 515 (15.5) 13 (13.1) 0.52
Beta-blockers 828 (25.0) 28 (28.3) 0.46
Insulin 335 (10.1) 13 (13.1) 0.33
Current episode, n (%)
Typical chest pain 2538 (79.0) 58 (65.2) 0.002
(n = 3213) (n = 89)
Resuscitated cardiac arrest 31 (0.9) 10 (10.1) <0.001
Segment-elevation myocardial infarction 1688 (50.9) 54 (54.5) 0.47
Anaemia on admission 689 (21.5) (n = 3202) 35 (36.8) (n = 95) <0.001
Admission glycaemia, mg/dl, mean ± SD 156 ± 77 203 ± 109 <0.001
Left ventricular ejection fraction, %, mean ± SD 53 ± 13 42 ± 16 <0.001
Medications within the first 48 h, n (%)
Low molecular-weight heparin 2159 (65.1) 45 (45.5) <0.001
Clopidogrel 2882 (86.9) 81 (81.8) 0.14
GP IIb-IIIa inhibitors 1236 (37.3) 35 (35.4) 0.69
Procedures during hospital stay, n (%)
Coronary angiography 2898 (87.4) 79 (79.8) 0.03
Percutaneous coronary intervention 2186 (65.9) 60 (60.9) 0.27
Coronary artery bypass graft 140 (4.2) 4 (4.0) 0.93
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Propensity-score-matched population
Separate analyses on propensity-score-matched popula-
tions confirmed these data: 1-year mortality in propensity-
score-matched cohorts of early survivors was significantly
higher in those with CS at the acute stage (HR: 2.49, 95%
CI: 1.43, 4.33, P = 0.001) (Figure 2 and Additional file 2
show this in more detail).
In contrast, 5-year mortality in propensity-score-matched
cohorts of 1-year survivors was similar in patients with CS
at the acute stage (25%) and in those without (23%) (HR:
1.11, 95% CI: 0.65, 1.91, P = 0.69) (Figure 3 and Additional
file 3 show this in more detail). In this population, similar
characteristics were correlated with long-term survival in
patients with or without CS (see Additional file 4).
Table 1 Baseline characteristics of patients surviving at 30 days and hospital discharge according to presence of
cardiogenic shock at the acute stage (Continued)
In-hospital complications, n (%)
Re-infarction 51 (1.5) 3 (3.0) 0.24
Stroke 19 (0.6) 4 (4.0) <0.001
Major bleeding 54 (1.6) 7 (7.1) <0.001
Transfusion 119 (3.6) 13 (13.1) <0.001
Ventricular fibrillation 44 (1.3) 12 (12.1) <0.001
Atrial fibrillation, new 150 (4.5) 25 (25.3) <0.001
Atrio-ventricular block 39 (1.2) 4 (4.0) 0.01
Medications at discharge, n (%)
Aspirin 3039 (92.3) 88 (90.7) 0.58
Clopidogrel 2662 (81.0) 78 (7906) 0.73
Statins 2760 (84.4) 70 (72.9) 0.002
Beta-blockers 2566 (78.7) 62 (65.3) 0.002
Angiotensin-converting enzyme inhibitors 2030 (62.9) 66 (68.8) 0.24
Angiotensin receptor blockers 270 (8.6) 4 (4.3) 0.15
Aldosterone receptor blockers 153 (4.9) 17 (18.3) <0.001
Loop diuretics 613 (19.7) 53 (57.6) <0.001
Digoxin 17 (0.5) 0 0.48
Nitrates 581 (18.6) 25 (27.2) 0.04
Amiodarone 232 (7.0) 24 (24.2) <0.001
Figure 1 Five-year survival in patients surviving at 30 days and hospital discharge according to the cardiogenic shock status.
HR, hazard ratio.
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Predictors of 1-year death in early survivors with shock
Using Cox multivariate analysis in the population of
patients with CS, most prognostic factors for death at
1 year were un-modifiable (older age, diabetes mellitus,
history of chronic kidney disease); likewise, patients with
STEMI had a markedly increased risk, compared with
NSTEMI patients (HR: 4.31; 95% CI 1.38, 13.44). When
STEMI patients were categorised according to use of
reperfusion therapy at the acute stage, and compared
with NSTEMI patients, lack of reperfusion in STEMI
patients was related to poorer survival (HR: 6.44, 95% CI:
1.91, 21.7 versus NSTEMI), while only a trend persisted
for STEMI patients with reperfusion therapy (HR: 2.87,
95% CI: 0.69, 11.9 versus NSTEMI). None of the discharge
medications were associated with improved survival, al-
though non-significant trends were observed for statins
(HR: 0.43, 95% CI: 0.10, 1.75) and clopidogrel (HR: 0.37,
95% CI: 0.08, 1.60).
Predictors of 5-year death in 1-year survivors with shock
In 1-year survivors who had CS at the acute stage, both
older age, and previous history of coronary artery disease
were associated with lower survival rate. Revasculari-
sation procedures during the initial hospital stay were
Figure 2 Landmark analysis: 1-year survival in propensity-score-matched cohorts of early survivors.
Patients atrisk
No cardiogenic shock 217 195 180 170 153
Cardiogenicshock 73 64 59 56 49
HR1.11(0.65 1.91)
P=0.69
No cardiogenic shock
Cardiogenic Shock
Figure 3 Landmark analysis: from one year to five years. Five-year survival in propensity-score-matched cohorts of patients surviving at one
year. HR, hazard ratio.
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associated with lower 5-year mortality (HR: 0.12, 95%
CI: 0.03, 0.42).
Discussion
The main finding of the present study in a contemporary
real-world population of AMI patients, is that early
survivors of CS still have higher mortality at 1 year, com-
pared with early survivors without CS. Beyond 1 year,
however, mortality up to 5 years becomes comparable
between patients with or without CS at the acute stage,
although the former have a more severe clinical profile.
Mortality is higher in STEMI patients with CS than in
NSTEMI patients with CS, and early revascularization is
associated with better long-term survival.
Most data available on the long-term outcome of CS
patients surviving the early phase of AMI were obtained
before major changes in AMI treatment were widely
implemented [3-5]. They are derived from populations
selected for inclusion into randomized trials, or less fre-
quently from real-life populations. Patient inclusion was
usually before the year 2000, at a time when outcomes
were notably poorer than nowadays [12].
Despite improved early management, early mortality
in CS patients remains considerably higher than that of
patients without CS [2,13]. In prior studies the reported
overall long-term survival of CS patients surviving the
early period varies widely from 12% to 73% at 5 years
[4-6,14,15]. In the large GUSTO-1 population of STEMI
patients [5], mortality at 11 years in early survivors was
45% in patients with CS, compared with 31% in patients
without CS. Patients included in the trial were relatively
young and had to fulfill the trial inclusion criteria, which
included early presentation after symptom onset, and all
received intravenous fibrinolytic therapy. Our patients
were enrolled in 2005, and more than 80% of patients
underwent myocardial revascularization. This clearly
differentiates our study, which is therefore clinically
relevant in the current era.
To the best of our knowledge, there has been only one
recent report on a large contemporary series of patients
with long-term follow up after CS [16]. The data, gath-
ered from the CRUSADE registry cross-linked with the
Medicare administrative database, were limited to older
(≥65 years) patients and only included NSTEMI patients.
Four-year survival in CS early survivors was 48%, com-
pared with 56.5% in non-CS survivors. Another novelty
of our study is that both STEMI and NSTEMI patients
were included.
In this population, 5-year survival of CS patients alive
after the acute phase was 59%. Improvements in primary
angioplasty and adjunctive pharmacotherapy are likely to
explain higher survival rates [4,5] in recent series. Of
note, a majority of our patients had undergone myocar-
dial revascularization during the initial hospital stay and
early revascularization was associated with better long-
term survival. In the SHOCK trial, early revascularization
significantly reduced 6-year mortality in early survivors by
41% (absolute risk reduction: 18%) [4]. Our study un-
derlines the potential interest of performing immediate
coronary reperfusion in CS, as it is also associated with
improved long-term survival. In this regard, developing
networks for the management of AMI patients, particu-
larly for the most severely affected patients, seems import-
ant to improve both early and long-term outcomes.
A consistent finding in all studies, including ours, is
similar mortality beyond 1 year in patients with or with-
out CS, regardless of the period studied or the inclusion
of STEMI or NSTEMI patients. The GUSTO-1 study
confirmed similar long-term survival between CS and
non-CS patients who were alive at 1 year. In the much
more recent CRUSADE registry in NSTEMI patients
65 years of age or older, no difference was observed
between patients with or without CS, once they had
survived the first months following the acute episode
[16]. The reasons for late survival becoming similar are
unclear, especially when considering the difference in
LVEF between patients who have developed CS and
those who have not. Mechanisms leading to CS include
left ventricular dysfunction, systemic inflammatory re-
sponse, activation of complement, release of cytokines,
and expression of inducible nitric oxide synthase [4,14,17].
The recent IABP SHOCK II trial confirmed the presence
of a high degree of inflammatory response in CS patients,
irrespective of the management strategy, and that CS
could be present even in the absence of profound LV
dysfunction (median LVEF 35%) [17]. The resolution of
severe ischaemia and/or neurohormonal abnormalities
may explain the potential reversibility of shock [4,14].
Also, the increasing use of medications such as beta-
blockers, ACE-inhibitors, ARBs or aldosterone blockers in
patients with CS during the hospital admission may have
participated in their improved long-term survival; of note,
the percentage of patients with CS receiving beta-blockers
increased from 68% at discharge to 81% at one year, and
the percentage of patients receiving either ACE-inhibitors
or ARBs marginally increased from 78% to 81% .
Strengths and limitations
Our study has the usual limitation of observational data.
Namely, no causality can be inferred from the associations
we observed. In addition, the sample size of patients with
CS was small, and subgroup analyses were therefore un-
realistic. We excluded patients admitted more than 48 h
after symptoms onset. These patients could have devel-
oped CS. Likewise, we were not able to assess the poten-
tial effect of implantable cardioverter defibrillators or of
cardiac resynchronization therapy, as very few patients
were implanted during the initial hospital stay (one in the
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CS group and six in the patients without CS). Conversely,
our population was extremely well-characterized and re-
flected a real-world population. Also, it included both
STEMI and NSTEMI patients and the rate of patients lost
to follow up was low.
Conclusion
The long-term outcome for early survivors of CS is
worse than that of patients without CS. Patients who
survive the first year after the acute event, however, have
a 5-year survival rate similar to that of non-CS patients.
This divergence between early, semi-early, and long-term
outcomes has remained consistent since the late 1980s
and underlines the importance of improving short-term
outcome by the early detection and management of CS,
including early myocardial revascularisation.
Key messages
 Early survivors of CS still have a higher mortality at
1 year, compared with early survivors without CS
 Beyond 1 year, however, mortality up to 5 years
becomes comparable between patients with or
without CS at the acute stage, although the former
have a more severe initial profile
 Mortality is higher in STEMI patients with CS than
in NSTEMI patients with CS
 Early revascularization is associated with better
long-term survival in CS patients following acute
myocardial infarction
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